PANCREATIC AND LUNG CANCERS DRIVEN BY MUTATIONS IN THE CANCER GENE KRAS
Dr Mara Zeissig, Group Head, T Cell Immunotherapy Laboratory
Tumour Inflammation and Immunotherapy Program
SAiGENCI – South Australian immunoGENomics Cancer Institute, Australia
RESEARCHER PROFILE
Filmed in Adelaide, Australia | December 2025
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
Dr Zeissig obtained her PhD at the University of Adelaide in 2020 with Prof Andrew Zannettino, where her research focused on the role of chemokine receptor CCR1 in the dissemination of the hematological malignancy multiple myeloma. She then undertook postdoctoral studies at Monash University with Prof Tony Tiganis, focusing on the role of protein tyrosine phosphotases PTPN2 and PTP1B on anti-tumour immunity in melanoma, breast, colon and liver cancers. In 2022 she joined the lab of Prof Kate Sutherland at WEHI. Here she conducted sophisticated CRISPR-Cas9 in vitro and in vivo screening to identify genetic determinants that influence response to KRAS inhibitors, and to identify novel immunotherapy targets in KRAS-mutant lung cancer. Her research has been published in high-impact journals including Science Advances (2022) and Cancer Discovery (2022). Dr Zeissig has been the recipient of numerous career awards and grants, including a Victorian Cancer Agency ECR Fellowship (2023-2026) and a Cure Cancer Research Grant (2023).
Immunotherapies such as CAR T cell therapy or Immune checkpoint inhibitors all harness the ability of cytotoxic T cells to recognise and kill tumour cells. However, approx. 80% of solid cancer patients do not respond to immunotherapy. This is due to both tumour intrinsic and extrinsic evasion mechanisms, the most crucial of these being 1) the immunosuppressive microenvironment that leads to T cell exhaustion and 2) loss of antigen and/or checkpoint ligand expression on tumour cells rendering the tumour unrecognisable by T cells. Importantly, there may be additional, undiscovered immune evasion mechanisms that could be exploited for immunotherapy.
Dr Zeissig’s lab is focused on understanding how cancers evade the immune system to identify new ways to enhance response to immunotherapy. In particular, her team work on lung and pancreatic cancers driven by mutations in the cancer gene KRAS. They utilise a range of tools including genetically engineered preclinical models of cancer, analysis of immune cell subsets, single-cell profiling and molecular biology techniques. They also harness large-scale genetic screening using CRISPR-Cas9 technology to find previously unknown targets and mechanisms that regulate response to immunotherapy.
Source: Supplied
https://orcid.org/0000-0003-3264-6546
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
-
Paediatric obesity prevention, nutrition and dietetics
Leveraging a systems-based and collaborative approach, Dr Littlewood over the past 25 years has driven research and data outcomes in the area of health and wellbeing. Dr Littlewood leads a dedicated team focused on making healthy happen for all Queenslanders, with a particular focus on improving health outcomes for the next generation.
-
Touched by bowel cancer and chasing science outcomes
Dr Josephine Wright is a Senior Research Fellow in the Gut Cancer group. She has been developing a translational network of labs, hospitals and clinics to enable validation of new approaches to prevent and treat colorectal and gastric cancer. Her key focus is studying human tumour organoids to better personalise therapy in cancer.
